What You Should Know:
– SimonMed Imaging, one of the largest outpatient medical imaging providers and radiology practices in the United States, today announced the launch of Ultrasound+, an AI-enabled ultrasound program.
– The program is powered by the FDA-cleared software, Koios DS, and is designed to assist with breast and thyroid cancer detection.
Embedding AI for Earlier and More Accurate Detection
Ultrasound+ represents a significant step in making advanced imaging technology accessible and affordable. The program uses advanced algorithms trained on millions of data points to analyze breast and thyroid ultrasound images in real-time. Acting as a second read for radiologists, the program is trained to identify subtle patterns linked to cancer that may not always be visible to the human eye.
SimonMed partnered with Koios Medical, the developer of Koios DS™, to integrate this AI technology system-wide across all locations offering ultrasound exams. Koios DS™ Breast is the only FDA-cleared AI cancer diagnosis software for breast ultrasound images and works as an expert on-demand second opinion, classifying suspicious lesions and aligning to a BI-RADS® category.
Measurable Benefits for Patients and Providers
Ultrasound+ is setting a new nationwide standard by making AI-enhanced, reimbursement-eligible technology available for breast and thyroid imaging at all locations.
For patients, the program delivers several key benefits:
- Earlier Detection: AI supports radiologists in catching subtle signs of breast and thyroid cancer sooner.
- Fewer Unnecessary Tests: Ultrasound+ reduces the need for unnecessary biopsies and minimizes additional imaging.
- Greater Peace of Mind: Patients receive results with added accuracy, consistency, and confidence.
Dr. John Simon, CEO and Founder of SimonMed Imaging, emphasized the dual benefit: “By making Ultrasound+ available at every location offering ultrasound exams, every patient who comes to SimonMed for a breast or thyroid ultrasound now benefits from AI-enhanced imaging. This reimbursable-eligible technology helps us detect cancers earlier, reduce unnecessary procedures, and ultimately improve outcomes for patients everywhere.”.
